Waldenström Macroglobulinemia: 2012 update on diagnosis, risk stratification, and management

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 503-510

  Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; HEMOGLOBIN; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; LENALIDOMIDE; PERIFOSINE; PREDNISONE; RITUXIMAB; SYNDECAN 1; THALIDOMIDE; VINCRISTINE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; MONOCLONAL ANTIBODY; PARAPROTEIN;

ALOPECIA; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD TOXICITY; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERVISCOSITY SYNDROME; INFECTION; LONG TERM CARE; LUNG TOXICITY; MEDICAL EDUCATION; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; OVERALL SURVIVAL; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK FACTOR; RISK MANAGEMENT; STEM CELL TRANSPLANTATION; STOMATITIS; THROMBOCYTE COUNT; WALDENSTROEM MACROGLOBULINEMIA; ADULT; AGED; AMYLOIDOSIS; BLOOD CELL COUNT; BLOOD VISCOSITY; BONE MARROW; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; HOSPITALIZATION; LYMPHOPROLIFERATIVE DISEASE; MIDDLE AGED; PATHOLOGY; REVIEW; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; AMYLOIDOSIS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD VISCOSITY; BONE MARROW; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN M; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; PARAPROTEINS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TUMOR BURDEN; WALDENSTROM MACROGLOBULINEMIA;

EID: 84859883028     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23192     Document Type: Article

References (83)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
2. Dimopoulos MA, Anagnostopoulos A. Waldenström's macroglobulinemia. Best Pract Res Clin Haematol 2005; 18: 747-765.
3. Bjorkholm M, Johansson E, Papamichael D, et al. Patterns of clinical presentation, treatment, and outcome in patients with Waldenström's macroglobulinemia: A two-institution study. Semin Oncol 2003; 30: 226-230.
4. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003; 30: 116-120.
5. Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenström macroglobulinemia incidence: A large population-based study. Cancer 2011; doi: 10.1002/cncr.26627. [Epub ahead of print].
6. Weiss BM, Minter A, Abadie J, et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. Am J Hematol 2011; 86: 475-478.
7. Stone MJ. Waldenström's macroglobulinemia: Hyperviscosity syndrome and cryoglobulinemia. Clin Lymph Myeloma 2009; 9: 97-99.
8. Baehring JM, Hochberg EP, Raje N, et al. Neurological manifestations of Waldenström macroglobulinemia. Nat Clin Pract Neurol 2008; 4: 547-556.
9. Berentsen S. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia. Clin Lymph Myeloma 2009; 9: 110-112.
10. Ghobrial IM, Uslan DZ, Call TG, et al. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response. Am J Hematol 2004; 77: 329-330.
11. Gruson B, Ghomari K, Beaumont M, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst 2011; 16: 180-185.
12. Klein CJ, Moon JS, Mauermann ML, et al. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci 2011; 38: 289-295.
13. Kastritis E, Kyrtsonis MC, Hatjiharissi E, et al. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. Am J Hematol 2011; 86: 479-483.
14. Waldenström J. Macroglobulinaemia. Acta Haematol 1958; 20: 33-39.
15. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenström's macroglobulinemia. Crit Rev Oncol Hematol 2008; 67: 172-185.
16. Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, et al. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999; 36: 104-114.
17. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. Clin Lymph Myeloma 2009; 9: 17-18.
18. Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Mod Pathol 2009; 22: 807-816.
19. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: A multicenter study. Clin Lymph Myeloma 2009; 9: 36-38.
20. Kitahara T, Umezu T, Ando K, et al. Non-random chromosomal deletion clustering at 20q in Waldenström macroglobulinemia. Hematology 2011; 16: 139-142.
21. Treon SP, Xu L, Zhou Y, et al. Whole genome sequencing reveals a widely expressed mutation (MYD88 L265P) with oncogenic activity in Waldenström's Macroglobulinemia [abstract]. Blood 2011; 118: 261.
22. Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009; 114: 2375-2385.
23. Stone MJ, Merlini G, Pascual V. Autoantibody activity in Waldenström's macroglobulinemia. Clin Lymph 2005; 5: 225-229.
24. Kyrtsonis MC, Levidou G, Korkolopoulou P, et al. CD138 expression helps distinguishing Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL). Clin Lymph Myeloma Leuk 2011; 11: 99-102.
25. Arcaini L, Varettoni M, Boveri E, et al. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Clin Lymph Myeloma Leuk 2011; 11: 103-105.
26. McMaster ML, Landgren O. Prevalence, clinical aspects, and natural history of IgM MGUS. Cytometry B Clin Cytom 2010; 78 (Suppl 1): S91-S97.
27. Phekoo KJ, Jack RH, Davies E, et al.; South Thames Haematology Specialist Committee. The incidence and survival of Waldenström's macroglobulinaemia in South East England. Leuk Res 2008; 32: 55-59.
28. Berenson JR, Anderson KC, Audell RA, et al. Monoclonal gammopathy of undetermined significance: A consensus statement. Br J Haematol 2010; 150: 28-38.
29. Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22: 1651-1657.
30. Schuster SR, Rajkumar SV, Dispenzieri A, et al. IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenström's macroglobulinemia. Am J Hematol 2010; 85: 853-855.
31. Leleu X, Xie W, Bagshaw M, et al. The role of serum immunoglobulin free light chain in response and progression in Waldenström macroglobulinemia. Clin Cancer Res 2011; 17: 3013-3018.
32. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification. Curr Hematol Malig Rep 2009; 4: 218-224.
33. Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol 2010; 28: 2902-2913; Erratum in: J Clin Oncol 2010; 28: 4664.
34. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009; 113: 4163-4170.
35. Treon SP, Agus TB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia. J Immunother 2001; 24: 272-279.
36. Gertz MA, Abonour R, Heffner LT, et al. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009; 147: 677-680.
37. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenström macroglobulinaemia. Br J Haematol 2006; 133: 158-164.
38. Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al; Greek Myeloma Study Group. Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 2010; 34: 1340-1343.
39. Kastritis E, Zervas K, Repoussis P, et al.; Greek Myeloma Study Group. Prognostication in young and old patients with Waldenström's macroglobulinemia: Importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymph Myeloma 2009; 9: 50-52.
40. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenström macroglobulinemia. Leuk Lymph 2008; 49: 1104-1107.
41. Dimopoulos MA, Kastritis E, Delimpassi S, et al. The International Prognostic Scoring System for Waldenström's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 2008; 93: 1420-1422.
42. Ricci F, Tedeschi A, Vismara E, et al. The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis. Clin Lymph Myeloma Leuk 2011; 11: 124-126.
43. Gertz MA, Fonseca R, Rajkumar SV. Waldenström's macroglobulinemia. Oncologist 2000; 5: 63-67.
44. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995; 10: 128-141.
45. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007 Jun; 33: 350-354.
46. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymph 2004; 45: 2047-2055.
47. Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenström macroglobulinaemia. Br J Haematol 2011; 154: 223-228.
48. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737-742.
49. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118: 195-198.
50. Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia. Clin Lymph Myeloma Leuk 2011; 11: 130-132.
51. Ramchandren S, Lewis RA. Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2009; 22: 480-485.
52. Ghobrial IM, Fonseca R, Greipp PR, et al.; Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: An Eastern Cooperative Oncology Group Study. Cancer 2004; 101: 2593-2598.
53. Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106: 2412-2420.
54. Treon SP, Hanzis C, Manning RJ, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenström Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011; 154: 357-362.
55. Treon SP, Soumerai JD, Hunter ZR, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood 2011; 118: 276-281.
56. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: An update of a US intergroup trial (SW0G S9003). Semin Oncol 2003; 30: 220-225.
57. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012; 118: 434-443.
58. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymph Myeloma 2009; 9: 62-66.
59. Buske C, Hoster E, Dreyling M, et al; German Low-Grade Lymphoma Study Group. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23: 153-161.
60. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25: 3344-3349.
61. Peinert S, Tam CS, Prince HM, et al. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk Lymph 2010; 51: 2188-2197.
62. Tedeschi A, Alamos SM, Ricci F, et al. Fludarabine-based combination therapies for Waldenström's macroglobulinemia. Clin Lymph Myeloma 2009; 9: 67-70.
63. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010; 24: 2056-2062.
64. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009; 27: 250-255.
65. Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150: 647-662.
66. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227-2232.
67. Chang H, Samiee S, Li D, et al. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenström's macroglobulinemia: A single center study of 22 cases. Leukemia 2004; 18: 1160-1162. Erratum in: Leukemia 2004; 18: 1564.
68. Gertz MA, Reeder CB, Kyle RA, Ansell SM. Stem cell transplant for Waldenström macroglobulinemia: An underutilized technique. Bone Marrow Transpl 2011; doi: 10.1038/bmt.2011.175. [Epub ahead of print].
69. Usmani S, Sexton R, Crowley J, Barlogie B. Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia. Clin Lymph Myeloma Leuk 2011; 11: 139-142.
70. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenström macroglobulinemia. Blood 2008; 112: 4452-4457.
71. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenström's macroglobulinemia. Clin Cancer Res 2009; 15: 355-360.
72. Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: Incidence and antigen-specificity of M proteins. Neurology 1987; 37: 1506-1514.
73. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27: 3830-3835.
74. Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. Clin Lymph Myeloma 2009; 9: 74-76.
75. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. J Clin Oncol 2010; 28: 1422-1428.
76. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol 2010; 85: 670-674.
77. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia. J Clin Oncol 2010; 28: 1408-1414.
78. Treon SP, Tripsas CK, Ioakimidis L, et al. Prospective, multicenter study of the mTOR inhibitor everolimus (RAD001) as primary therapy in Waldenström's Macroglobulinemia [abstract]. Blood 2011; 118: 2951.
79. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res 2010; 16: 1033-1041.
80. Garcia-Sanz R, Ocio EM. Novel treatment regimens for Waldenström's macroglobulinemia. Expert Rev Hematol 2010; 3: 339-350.
81. Rummel MJ, Niederle N, von Grunhagen U, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line-treatment in patients with indolent lymphomas and Waldenström's macroglobulinemia [abstract]. The Sixth International Workshop on Waldenström's Macroglobulinemia, Oct 6-10, 2010, Venice, Italy.
82. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymph Myeloma Leuk 2011; 11: 133-135.
83. Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85: 824-833.